Host: John J. Russell, MD 


Guest: Anne Peters, MD, CDE 


Many patients with type 2 diabetes mellitus cannot be controlled with standard insulin agents due to obesity, insulin resistance, high risk of hypoglycemia, low adherence due to high injection burden, and the need for frequent glucose monitoring. Drs. Peters and Russell will review patient cases, and share practical information on concentrated insulins, including criteria for selection, switching strategies and dosing regimens, providing true practice-based learning particularly for clinicians in different geographic locations with high incidence rates of diabetes.

Improving Glycemic Control: Reducing Patient Burden, The Rationale for Concentrated Insulins in Type 2 Diabetes Mellitus

As the number of Americans living with diabetes continues to rise, staying up to date on the latest diabetes research is more essential than ever to help patients achieve glucose control. With Diabetes Discourse, you’ll hear from diabetes and endocrinology experts on emerging research, diagnostic and treatment strategies, and various elements that impact a patient’s disease course, including risk factors, vitamin and mineral supplementation, physical activity, and kidney disease.
Because when it comes to diabetes, glucose control is just the beginning.

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Health

Alternative Health

Self-Help

Sexuality

Fitness & Nutrition

Host: John Buse, MD, PhD 


  Guest: Kim Boggess, MD 



  
    The most common forms of diabetes encountered in pregnant patients include gestational diabetes and preexisting type 2 diabetes. So how does adding metformin to insulin treatment help these patients? Join Dr. John Buse as he talks about the MOMPOD Trial with lead author, Dr. Kim Boggess, Professor of Maternal Fetal Medicine at the University of North Carolina at Chapel Hill. 

Concentrating on the MOMPOD Trial for Metformin Plus Insulin

Guest: R. Paul Wadwa, M.D. 



  
    Since young kids have a different activity level and diet than older kids or adult patients, controlling type 1 diabetes in younger patients can be more challenging, and there tends to be more variability in their blood sugars. However, a recent study identified that hybrid closed-loop technology could help give children with type 1 diabetes the best outcomes and quality of life. To learn more, tune in with Dr. Paul Wadwa, Professor of Pediatrics and the Medical Director of the Pediatric Clinic at the Barbara Davis Center for Diabetes at University of Colorado Anschutz Medical Campus.

Utilizing Hybrid Closed-Loop Technology for T1D Pediatric Patients

Host: Carol Wysham, MD 


  Guest: A. Michael Lincoff, MD 



  
    Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in patients who are overweight or obese but do not have diabetes. Not only did semaglutide reduce the risk of cardiovascular death, myocardial infarction, and stroke by 20 percent, but it also significantly reduced the risk of developing diabetes. Dive further into the findings and implications with Dr. Carol Wysham and study author Dr. Michael Lincoff.

Semaglutide Reduces CV Events in Non-Diabetic, Overweight Patients

Host: John Buse, MD, PhD 


  Guest: Louis J. Aronne, MD, FTOS 



  
    In the SURMOUNT-4 trial, 100 patients with obesity were on tirezpatide for 9 months, and the average weight loss was 20.9 percent. The patients were then randomized to receive either placebo with behavioral intervention or tirzepatide for another year, and the patients in the former group regained a significant amount of weight. Dive further into the study’s findings and implications with Dr. John Buse and Dr. Louis Aronne, the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medical College in New York.

Overcoming Obesity: Insights from the SURMOUNT-4 Trial

Host: John Buse, MD, PhD 


  Guest: Mary de Groot, PhD 



  
    The prevalence of diabetes-related stigma is alarmingly high. In fact, four in five adults have reported experiencing some form of diabetes stigma at some point in their lives. To learn how we as healthcare providers can help reduce this burden for our patients with diabetes, Dr. John Buse speaks with Dr. Mary de Groot, Professor of Medicine and the Associate Vice Chair for Wellness at Indiana University School of Medicine.

Improving Glycemic Control: Reducing Patient Burden, The Rationale for Concentrated Insulins in Type 2 Diabetes Mellitus

Download our free app to listen on your phone